Diamyd Medical AB (publ) (FRA:DMN)

Market Cap	191.05M +145.6%
Revenue (ttm)	33.96K +98.9%
Net Income	-18.80M
EPS	-0.15
Shares Out	n/a
PE Ratio	n/a
Forward PE	46.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,300
Open	1.292
Previous Close	1.406
Day's Range	1.292 - 1.292
52-Week Range	0.649 - 1.800
Beta	n/a
RSI	46.79
Earnings Date	Mar 25, 2026

About Diamyd Medical AB

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to devel...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 41
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DMN

Financial Performance

In fiscal year 2025, Diamyd Medical AB's revenue was 130,000, a change of 0.00% compared to the previous year's 130,000. Losses were -169.78 million, 11.8% more than in 2024.

Financial numbers in SEK